

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

J. M. Loune  
Signature of Authorized Individual\*

6/17/2020  
Date

JOE LOUNE  
Printed Name of Authorized Individual

6/17/2020  
Date

\*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

**SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)**

Case No.	Debtor Entity Name:	Net Receipts <sup>2</sup>	Net Disbursements <sup>1</sup>
19-23648	PURDUE PHARMA INC.	\$ 67,519	\$ 967,053
19-23649	PURDUE PHARMA L.P.	102,031,998	142,282,795
19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	-
19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	31,708
19-23652	PURDUE PHARMACEUTICALS L.P.	-	3,425,113
19-23653	IMBRIUM THERAPEUTICS L.P.	-	1,454,483
19-23654	ADLON THERAPEUTICS L.P.	-	3,826,300
19-23655	GREENFIELD BIO VENTURES L.P.	-	198,052
19-23656	SEVEN SEAS HILL CORP.	-	-
19-23657	OPHIR GREEN CORP.	-	-
19-23658	PURDUE PHARMA OF PUERTO RICO	-	5,671
19-23659	AVRIO HEALTH L.P.	6,411	3,718,535
19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	16,793
19-23661	PURDUE NEUROSCIENCE COMPANY	-	-
19-23662	NAYATT COVE LIFESCIENCE INC.	-	490,581
19-23663	BUTTON LAND L.P.	-	-
19-23664	PAUL LAND INC.	-	-
19-23665	QUIDNICK LAND L.P.	-	-
19-23666	RHODES ASSOCIATES L.P.	-	-
19-23667	RHODES PHARMACEUTICALS L.P.	8,502,042	14,038,298
19-23668	RHODES TECHNOLOGIES	4,738,396	6,938,511
19-23669	UDF LP	-	-
19-23670	SVC PHARMA LP	-	255,336
19-23671	SVC PHARMA INC.	-	-
<b>Totals:</b>		<b>\$ 115,346,366</b>	<b>\$ 177,649,229</b>

**Footnotes**

- 1) The Net Disbursements exclude intercompany transactions among Debtors
- 2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
June 30, 2020

**BANK ACCOUNT BALANCES (\$)**

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	\$ 750,229
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,864,178
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,022,575
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	3,507,873
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,663,734
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Money Market Account	201,276,322
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Money Market Account	100,296,603
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx8720	Money Market Account	100,190,784
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	53,820,969
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	584,537,765
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	20,239,541
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	211,555
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx6017	Trust	15,148,077
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,272,196
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	59,173,853
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,017,014
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	125,324,030
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,390,740
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx4018	Trust	25,104,051
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	1,231,609
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	125,926
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
June 30, 2020

**BANK ACCOUNT BALANCES (\$)**

Debtor	Bank	Account Number	Description	Balance as of Month End
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-
Rhodes Technologies	JP Morgan Chase	xxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
<b>Total</b>				<b>\$ 1,346,520,289</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

**CONSOLIDATED STATEMENT OF OPERATIONS (\$M)**<sup>1,2</sup>  
**Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.**

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Net Sales	\$ 73	\$ 472	\$ 783
Cost of Goods Sold	(18)	(94)	(194)
Gross Profit	55	378	588
Sales and Promotion	(8)	(54)	(92)
Research and Development	(8)	(35)	(69)
General and Administrative	(8)	(48)	(88)
Legal Fees - Ordinary Course	0	(5)	(8)
Medical Affairs	(2)	(15)	(26)
Milestones & Alliances	(1)	(5)	(6)
Health Care Reform Fee	(2)	(6)	(10)
Other US	(0)	(1)	(2)
Incentive Bonus	(4)	(21)	(37)
Total Operating Expenses	(32)	(190)	(338)
Operating Profit	23	188	251
Legal Fees - Non-Recuring	(36)	(180)	(277)
Other	(7)	(12)	(19)
Total Non-Operating Expenses	(43)	(192)	(296)
Profit	\$ (20)	\$ (4)	\$ (45)

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000) <sup>1,2</sup>

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Management Fee Income	\$ 29	\$ 175	\$ 290
General and Administrative Expenses	(1)	(23)	(52)
Operating Income	28	152	238
		-	
Income from Unconsolidated Associated Companies	140	249	(677)
Total Other Income	140	249	(677)
		-	
Pre-Tax Income	168	401	(439)
		-	
Income Tax Provision	(45)	(108)	104
		-	
Net Income	\$ 123	\$ 293	\$ (335)

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
June 30, 2020

CONSOLIDATED BALANCE SHEET (\$M) <sup>1,2</sup>	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
<b>ASSETS</b>	
<b>CURRENT ASSETS</b>	
Cash & Cash Equivalents	\$ 1,060
Available For Sale Investments	1
Accounts Receivable, Net	82
Due From Associated Companies	7
Other Receivables	2
Inventories, Net	111
Prepaid Expenses & Other Current Assets	64
Restricted Cash	138
<b>TOTAL CURRENT ASSETS</b>	<b>1,465</b>
Property and Equipment, net	135
Investments at Cost	36
Investments in Associated Companies	-
Restricted Cash - Long-Term	147
Intangible Assets, Net	98
Other Assets	-
<b>TOTAL ASSETS</b>	<b>\$ 1,881</b>
<b>LIABILITIES AND EQUITY</b>	
<b>CURRENT LIABILITIES</b>	
Accounts Payable	\$ 51
Accrued Expenses	322
Due to Associated Companies	1
<b>TOTAL CURRENT LIABILITIES</b>	<b>374</b>
Other Liabilities	97
Due to Associated Companies	11
Liabilities Subject to Compromise <sup>3</sup>	3,017
<b>TOTAL LIABILITIES</b>	<b>3,499</b>
<b>EQUITY</b>	
Retained Earnings & Partners' Capital	(1,572)
Accumulated Other Comprehensive Loss	(46)
<b>TOTAL EQUITY</b>	<b>(1,618)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$ 1,881</b>

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

In re: **PURDUE PHARMA L.P., et al.,**  
**Debtors**

Case No.: 19-23649 (RDD)  
June 30, 2020

**PURDUE PHARMA, INC. BALANCE SHEET (\$000) <sup>1,2</sup>**

	Book Value
<b>Assets</b>	
Currents assets:	
Cash and cash equivalents	\$ 1,057
Prepaid expenses	267
Due from Associated Companies	328
Other receivables	-
<b>Total current assets</b>	<b>1,652</b>
Investments	10,570
Deferred income taxes	147
<b>Total assets</b>	<b>\$ 12,369</b>
<b>Liabilities and equity</b>	
Current liabilities:	
Accounts payable	\$ 463
Due to Associated Companies	383
Accrued Expenses	178
<b>Total liabilities</b>	<b>1,024</b>
Common stock	1
Additional paid-in capital	499
Retained earnings	10,910
Accumulated other comprehensive loss	(65)
<b>Total equity</b>	<b>11,345</b>
<b>Total liabilities and equity</b>	<b>\$ 12,369</b>

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020


**SCHEDULE OF POST PETITION TAXES**

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



\_\_\_\_\_  
Signature

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Compensation</b>		
Chomiak, Caroline	\$ -	\$ 261,662
Kesselman, Marc L <sup>2</sup>	163,504	2,623,338
Landau, Craig J	235,864	2,380,473
Lowne, Jonathan R	84,910	1,231,697
Lundie, David R	66,841	1,008,069
Mancinelli II, Vincent F	41,042	591,197
Mazzi, Christian	-	439,030
Medeiros, Paul	56,095	797,157
Shamblen, Randy	40,170	580,843
Strassburger, Philip C	77,702	1,053,272
<b>Total Compensation</b>	<b>766,128</b>	<b>10,966,738</b>
<b>Director Fees</b>		
Boer, F Peter	175,000	700,000
Buckfire, Kenneth A	175,000	700,000
Cola, Michael	175,000	700,000
Collins, Michael J	-	25,000
Dubel, John	175,000	700,000
Miller, Robert S	208,333	1,666,667
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	175,000	700,000
<b>Total Director Fees</b>	<b>1,083,333</b>	<b>5,216,667</b>
<b>T&amp;E Reimbursements</b>		
Boer, F Peter	-	10,907
Buckfire, Kenneth A	386	1,565
Chomiak, Caroline	-	30,408
Cola, Michael	-	1,388
Debone, Louis	-	1,245
Dubel, John	-	4,714
Kesselman, Marc L	50	49,365
Landau, Craig J	818	65,111
Lowne, Jonathan R	-	1,764
Lundie, David R	550	28,913
Mancinelli II, Vincent F	39	41,240
Mazzi, Christian	-	3,734
Medeiros, Paul	(1,905)	36,103
Miller, Robert S	-	9,765
Pickett, Cecil	-	1,298
Shamblen, Randy	39	11,470
Strassburger, Philip C	280	15,995
<b>Total T&amp;E Reimbursements</b>	<b>258</b>	<b>314,985</b>
<b>Housing Payments</b>		
Kesselman, Marc L	4,673	51,176
<b>Total Housing Payments</b>	<b>4,673</b>	<b>51,176</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Indemnification Payments</b>		
Baker, Stuart D <sup>3</sup>	240,480	811,476
Butcher, James A	-	527
Friedman, Michael	367	136,865
Landau, Craig J	117,908	955,801
Motahari, Saeed	9,643	24,208
Roncalli, Anthony	145,579	215,643
Stewart, John	44,070	135,125
Tinney, Mark	3,435	1,036,338
Purdue Pharma Inc Independent Directors <sup>4</sup>	162,269	953,111
<b>Total Indemnification Payments</b>	<b>723,751</b>	<b>4,269,095</b>
<b>Payments to Independent Associated Companies</b>		
Mundibiopharma Ltd	-	55,332
Mundipharma DC BV	58,522	263,503
Mundipharma International Technical Operations Ltd.	-	4,479
Mundipharma IT Services LTD	-	278,603
Mundipharma Laboratories GmbH	412,664	683,792
Mundipharma Research LTD	-	63,532
Mundipharma Singapore Holdings Pte Ltd	-	60,675
One Stamford Realty L.P.	1,058,096	7,455,127
Pharmaceutical Research Associates Inc.	-	485,533
Purdue Pharma Canada	371,426	3,411,634
TXP Services Inc. <sup>5</sup>	440,113	5,462,519
<b>Total Payments to Independent Associated Companies</b>	<b>2,340,820</b>	<b>18,224,729</b>
<b>Total Payments to Insiders</b>	<b>\$ 4,918,963</b>	<b>\$ 39,043,390</b>

**Footnotes**

- 1) Represents payments made since the Commencement Date.
- 2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.
- 3) Indemnification payments made in June 2020 on behalf of Stuart D. Baker were inadvertently in amounts exceeding the 50% reimbursement rate approved by the Special Committee of Purdue Pharma Inc.'s Board of Directors, totaling \$12,390. Overpayments will be reversed through future invoice credits, repayment from respective law firms, and/or reimbursement from Stuart D. Baker.
- 4) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snyderman, Ralph.
- 5) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1)</sup>
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	\$ 8,533,961	\$ 35,633,282
AlixPartners, LLP	2,806,196	8,512,164
PJT Partners LP	204,000	986,456
Ernst & Young	-	480,000
Prime Clerk LLC	4,075,671	39,636,743
Total Estate Professionals	15,619,828	85,248,646
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	3,971,008	14,671,034
Bayard, P.A.	-	768,164
Cole Schotz P.C.	446,415	710,825
Jefferies LLC	198,480	1,182,636
KPMG	-	825,351
Province, Inc.	996,891	5,834,316
Kurtzman Carson Consultants LLC	27,756	51,492
Total Creditor Committee Professionals	5,640,549	24,043,817
<i>Ad Hoc Committee Professionals</i>		
Kramer Levin Naftalis & Frankel LLP	-	2,505,169
Brown Rudnick LLP	-	1,335,171
Gilbert LLP	-	870,501
Otterbourg PC	125,559	728,114
FTI Consulting, Inc	793,933	3,853,992
Compass Lexecon	-	-
Coulter & Justice	-	-
Total Ad Hoc Committee Professionals	919,492	9,292,946
<i>Special Counsel to the Debtors</i>		
Arnold Porter & Kaye Scholer	195,711	826,394
Dechert LLP	-	-
Jones Day	-	1,116,723
King & Spalding LLP	1,016,897	6,312,083
Skadden, Arps, Slate, Meagher & Flom LLP	137,728	3,285,950
Wilmer Cutler Pickering Hale and Door LLP	-	-
Total Special Counsel Professionals	1,350,336	11,541,150
The Law Offices of Kenneth Feinberg (Mediator)	500,000	2,002,648
Phillips ADR (Mediator)	500,000	2,004,089
Bielli & Klauder, LLC (Fee Examiner)	-	-
Tom Vilsack (Court appointed monitor)	14,250	69,875
Ernst & Young (Canada), Court Appointed Information Officer	-	178,591
Total Retained Restructuring Professional Fees	\$ 24,544,456	\$ 134,381,762

Footnotes

- 1) Represents payments made since the Commencement Date
- 2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period June 1, 2020 to June 30, 2020

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?		X	
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	